Management of Hyponatremia - Latest Guidelines

Definition and Classification

Step 1 - Assess Symptom Severity

• Severe (emergency): Seizures, coma, respiratory distress, obtundation, vomiting
• Moderate: Confusion, headache, nausea, unsteady gait
• Mild/Asymptomatic: Fatigue, mild cognitive changes

Step 2 - Treat by Acuity and Volume Status

A. Acute Symptomatic Hyponatremia (< 48 hours, severe symptoms)

• 3% hypertonic saline 100 mL IV bolus over 10 minutes, repeated up to 2 times (i.e., up to 3 boluses total) - Goldman-Cecil Medicine, p. 1202
• Goal: raise Na+ by 4-6 mmol/L within 1-2 hours to reduce cerebral edema
• No mandatory upper correction limit in true acute hyponatremia; do not reverse inadvertent overcorrection in this setting
• Continuous infusion alternative: 3% NaCl at 0.5-2 mL/kg/hour for mild-moderate symptoms with low herniation risk

B. Chronic Hyponatremia (> 48 hours or unknown duration)

Correction Targets (Standard / Current Guidelines):

• Alcoholism / malnutrition
• Liver disease
• Hypokalemia
• Serum Na+ ≤ 105 mmol/L
• Duration > 48 hours with any of the above
• National Kidneys Foundation Primer on Kidney Diseases, 8e, p. 96

If Overcorrection Occurs (Na+ rises too fast):

1. Desmopressin (dDAVP) 2-4 mcg IV/SC every 8 hours - reduces free water loss
2. 5% dextrose water (D5W) 3 mL/kg/hour IV - replaces free water
3. Dexamethasone 4 mg IV every 6 hours for 24-48 hours if significant overcorrection has occurred
4. Check serum Na+ hourly until at target - Goldman-Cecil Medicine, p. 1203

Step 3 - Volume-Based Treatment Strategy

Hypovolemic Hyponatremia

• 0.9% isotonic NaCl at a rate appropriate for volume depletion
• If diuretic-induced: add K+ 30-40 mmol/L to fluids even if serum K+ is normal (total body K+ depletion common)
• Watch for "aquaresis" - once volume is restored, AVP suppression can cause a brisk water diuresis and unexpectedly rapid Na+ rise - monitor hourly urine output and osmolality
• If urine osmolality drops rapidly: stop saline, give hypotonic fluids or dDAVP

Euvolemic Hyponatremia (usually SIADH)

1. Fluid restriction (first line): typically 500-800 mL/day below urine output
2. Salt tablets (oral sodium supplementation)
3. Urea (oral) - promotes osmotic diuresis; 15-30 g/day; underutilized but effective

• Tolvaptan 15 mg orally once daily (max 60 mg/day) - for euvolemic or hypervolemic hyponatremia
• Conivaptan IV - for inpatient use
• Contraindicated in cirrhosis due to hepatotoxicity risk
• High risk of overcorrection - initiate in monitored settings only

1. Demeclocycline - blocks renal tubular response to ADH; 300-600 mg twice daily; slower onset (days)

Hypervolemic Hyponatremia (Heart failure / Cirrhosis)

• Sodium and water restriction (target fluid intake 1-1.5 L/day in cirrhosis)
• Optimize underlying cause - diuretics, treatment of heart failure
• Loop diuretics (furosemide) remove relatively more water than salt when combined with fluid restriction
• Tolvaptan is approved for heart failure-associated hyponatremia but not recommended in cirrhosis (hepatotoxicity)
• In cirrhosis: IV albumin, discontinue diuretics if hyponatremia is severe, consider oral vasoconstrictors (midodrine/terlipressin)

Step 4 - SIADH: Diagnosing Underlying Cause

Step 5 - Sodium Correction Formula

ΔNa+ = (Infusate Na+ - Serum Na+) / (Total body water + 1)

• Total body water = 0.6 × weight (males), 0.5 × weight (females), 0.45 × elderly
• Useful for planning but must be supplemented with frequent monitoring every 2-4 hours - clinical response often differs from prediction

Monitoring

• Serum Na+ every 2-4 hours during active correction
• Hourly during rapid correction or high-ODS-risk patients
• Urine osmolality and urine Na+ to guide ongoing management
• Spot-check Na+ at 6 and 24 hours post-initiation of therapy

Key Controversies: 2025 Evidence Update

• Rapid correction (≥ 8-10 mmol/L/24h) was associated with 32 fewer in-hospital deaths per 1000 patients vs. slow correction (OR 0.67, 95% CI 0.55-0.82)
• Very slow correction (< 4-6 mmol/L/24h) was associated with 221 fewer deaths per 1000 with rapid correction
• Rapid correction was not associated with significantly increased ODS risk

Clinical implication: This challenges the traditional blanket restriction to < 10-12 mmol/L/24h. However, major expert societies currently maintain conservative correction limits pending prospective RCT data, particularly for patients with known chronic hyponatremia. A 2024 CJASN editorial ("Treatment Guidelines for Hyponatremia: Stay the Course") recommends against changing current practice based on retrospective observational data alone.

Special Situations

Cirrhosis (AGA 2025 Practice Guideline, PMID 41114681)

• Outpatient: fluid restriction 1-1.5 L/day, modify/discontinue diuretics
• Inpatient (severe/symptomatic): Na+ and water restriction + IV albumin based on volume assessment + oral vasoconstrictors
• No tolvaptan (hepatotoxicity)
• Refractory cases: TIPS referral; liver transplant evaluation

Thiazide-Induced Hyponatremia

• Stop thiazide; replace with K+ supplementation
• Usually responds well to isotonic saline
• May have brisk aquaresis on correction - monitor closely

Exercise-Associated Hyponatremia

• Treat as acute hyponatremia
• 3% NaCl bolus for symptomatic cases
• Do not give hypotonic fluids (worsens cerebral edema)

Postoperative Hyponatremia

• Often acute (< 48 hours); treat aggressively with 3% NaCl if symptomatic
• High risk in women, elderly, small body habitus receiving hypotonic perioperative fluids

Summary Algorithm

Hyponatremia (Na+ < 135 mmol/L)
        |
    Severe symptoms? (seizures, coma)
        |
   YES → 3% NaCl 100 mL bolus x3, target +4-6 mmol/L in 1-2h
   NO  → Assess volume status
            |
     Hypovolemic → Isotonic NS ± K+
     Euvolemic   → Fluid restriction → salt tabs/urea → vaptan (if SIADH)
     Hypervolemic → Fluid + Na restriction, treat cause, loop diuretics ± vaptan
        |
    Chronic? → Correct ≤8-10 mmol/L in 24h (≤8 if ODS risk factors)
             → Goal: 6-8 mmol/L/24h
             → Monitor Na+ every 2-4h
             → If overcorrected: dDAVP + D5W

• National Kidneys Foundation Primer on Kidney Diseases, 8th ed., Chapter 7 (Hyponatremia)
• Goldman-Cecil Medicine International Edition, Chapter 102 (Disorders of Sodium and Water)
• Ayus JC et al. Correction Rates and Clinical Outcomes in Severe Hyponatremia - JAMA Intern Med 2025 (Systematic Review & Meta-Analysis, 11,811 patients)
• Orman ES et al. AGA Clinical Practice Update - Hyponatremia in Cirrhosis - Gastroenterology 2025
• Beck J. Treatment of Chronic Hyponatremia and Controversy about ODS - Best Pract Res Clin Endocrinol Metab 2026